IceCure Receives Israeli AMAR Approval for Use of its Freezing Technology in Specific Indications, Following an Earlier General Approval

The AMAR approval allows for freezing of benign and malignant tumors including breast, lungs, bones, liver, lymphatic tissue, lymph nodes and endocrine glands. This achievement comes hot on the back of the company receiving a Class 3 CPT code from the American Medical Association that enables providers to apply for reimbursement for procedures using cryoablation […]

IceCure featured in the leading interventional oncology news outlet, Interventional News

Kenneth-R-Tomkovich- lead PI of ICE3 cryoablation breast cancer study

IceCure’s landmark US clinical trial, ICE3, for nitrogen-based cryoablation of small, low-risk, early stage malignant breast tumors without subsequently removing them, featured in Interventional News. Cryoablation shows promise in treating low-risk breast cancers.  “If the positive preliminary findings are maintained as the patients enrolled in the study continue to be monitored, that will serve as […]

IceCure featured in the leading news education publication, Healio


The promise of cryotherapy as an alternative treatment for a specific group of [patients with] breast cancer.” Kenneth Tomkovich MD, radiologist at Princeton Radiology and director of breast imaging and interventions at CentraState Medical Center in Freehold, New Jersey discusses the positive preliminary findings of the ICE3 clinical trials. Read more >